258 related articles for article (PubMed ID: 17852451)
1. Application of PRV-1 mRNA expression level and JAK2V617F mutation for the differentiating between polycytemia vera and secondary erythrocytosis and assessment of treatment by interferon or hydroxyurea.
Tutaeva V; Misurin AV; Michiels JJ; Rozenberg JM; Sokolova MA; Ivanova VL; Kolosheinova TI; Manakova TE; Levina AA; Semenova EA; Khoroshko ND
Hematology; 2007 Dec; 12(6):473-9. PubMed ID: 17852451
[TBL] [Abstract][Full Text] [Related]
2. Unclassifiable non-CML classical myeloproliferative diseases with microcytosis: findings indicating diagnosis of polycythemia vera masked by iron deficiency.
Aladağ E; Aksu S; Demiroğlu H; Sayınalp N; Göker H; Haznedaroğlu İC; Özcebe Oİ; Büyükaşık Y
Turk J Med Sci; 2019 Oct; 49(5):1560-1563. PubMed ID: 31652037
[TBL] [Abstract][Full Text] [Related]
3. The utility of testing erythropoietin level in polycythemia diagnosis.
Ismail A; Abdalla E; Aqel A; Fadul A; Ahmed A; Alsayed A; Musa M; Yassin MA
Hematology; 2023 Dec; 28(1):2269510. PubMed ID: 37843428
[TBL] [Abstract][Full Text] [Related]
4. [JAK2 V617F mutation burden and its clinical implications in 415 patients with myeloproliferative neoplasm].
Liu Y; Liu C; He N; Wang M; Zhang X; Tang D; Ji C; Ma D
Zhonghua Xue Ye Xue Za Zhi; 2015 Mar; 36(3):191-5. PubMed ID: 25854460
[TBL] [Abstract][Full Text] [Related]
5. [Clinical and laboratory features compared between JAK2 exon12 and JAK2 V617F mutated polycythemia vera].
Liu D; Zhang PH; Xu ZF; Ma J; Qin TJ; Qu SQ; Sun XJ; Li B; Pan LJ; Jia YJ; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2022 Feb; 43(2):107-114. PubMed ID: 35381670
[No Abstract] [Full Text] [Related]
6. JAK2 V617F allele burden in polycythemia vera: burden of proof.
Moliterno AR; Kaizer H; Reeves BN
Blood; 2023 Apr; 141(16):1934-1942. PubMed ID: 36745865
[TBL] [Abstract][Full Text] [Related]
7. Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea.
Yacoub A; Mascarenhas J; Kosiorek H; Prchal JT; Berenzon D; Baer MR; Ritchie E; Silver RT; Kessler C; Winton E; Finazzi MC; Rambaldi A; Vannucchi AM; Leibowitz D; Rondelli D; Arcasoy MO; Catchatourian R; Vadakara J; Rosti V; Hexner E; Kremyanskaya M; Sandy L; Tripodi J; Najfeld V; Farnoud N; Papaemmanuil E; Salama M; Singer-Weinberg R; Rampal R; Goldberg JD; Barbui T; Mesa R; Dueck AC; Hoffman R
Blood; 2019 Oct; 134(18):1498-1509. PubMed ID: 31515250
[TBL] [Abstract][Full Text] [Related]
8. Erlotinib effectively inhibits JAK2V617F activity and polycythemia vera cell growth.
Li Z; Xu M; Xing S; Ho WT; Ishii T; Li Q; Fu X; Zhao ZJ
J Biol Chem; 2007 Feb; 282(6):3428-32. PubMed ID: 17178722
[TBL] [Abstract][Full Text] [Related]
9. Givinostat: an emerging treatment for polycythemia vera.
Chifotides HT; Bose P; Verstovsek S
Expert Opin Investig Drugs; 2020 Jun; 29(6):525-536. PubMed ID: 32693648
[TBL] [Abstract][Full Text] [Related]
10. Iron is a modifier of the phenotypes of JAK2-mutant myeloproliferative neoplasms.
Stetka J; Usart M; Kubovcakova L; Rai S; Rao TN; Sutter J; Hao-Shen H; Dirnhofer S; Geier F; Bader MS; Passweg JR; Manolova V; Dürrenberger F; Ahmed N; Schroeder T; Ganz T; Nemeth E; Silvestri L; Nai A; Camaschella C; Skoda RC
Blood; 2023 Apr; 141(17):2127-2140. PubMed ID: 36758212
[TBL] [Abstract][Full Text] [Related]
11. Proinflammatory phenotype of iPS cell-derived JAK2 V617F megakaryocytes induces fibrosis in 3D in vitro bone marrow niche.
Flosdorf N; Böhnke J; de Toledo MAS; Lutterbach N; Lerma VG; Graßhoff M; Olschok K; Gupta S; Tharmapalan V; Schmitz S; Götz K; Schüler HM; Maurer A; Sontag S; Küstermann C; Seré K; Wagner W; Costa IG; Brümmendorf TH; Koschmieder S; Chatain N; Castilho M; Schneider RK; Zenke M
Stem Cell Reports; 2024 Feb; 19(2):224-238. PubMed ID: 38278152
[TBL] [Abstract][Full Text] [Related]
12. Novel germline JAK2
Song J; Lanikova L; Kim SJ; Papadopoulos N; Meznarich J; Constantinescu SN; Parsegov B; Prchal JF; Prchal JT
Am J Hematol; 2024 Apr; ():. PubMed ID: 38629639
[TBL] [Abstract][Full Text] [Related]
13. SRSF2 mutation reduces polycythemia and impairs hematopoietic progenitor functions in JAK2V617F-driven myeloproliferative neoplasm.
Yang Y; Abbas S; Sayem MA; Dutta A; Mohi G
Blood Cancer J; 2023 Nov; 13(1):171. PubMed ID: 38012156
[TBL] [Abstract][Full Text] [Related]
14. Moving toward disease modification in polycythemia vera.
Bewersdorf JP; How J; Masarova L; Bose P; Pemmaraju N; Mascarenhas J; Rampal RK
Blood; 2023 Nov; 142(22):1859-1870. PubMed ID: 37729609
[TBL] [Abstract][Full Text] [Related]
15. JAK2 unmutated erythrocytosis: 2023 Update on diagnosis and management.
Gangat N; Szuber N; Tefferi A
Am J Hematol; 2023 Jun; 98(6):965-981. PubMed ID: 36966432
[TBL] [Abstract][Full Text] [Related]
16. A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia.
Mascarenhas J; Kosiorek HE; Prchal JT; Rambaldi A; Berenzon D; Yacoub A; Harrison CN; McMullin MF; Vannucchi AM; Ewing J; O'Connell CL; Kiladjian JJ; Mead AJ; Winton EF; Leibowitz DS; De Stefano V; Arcasoy MO; Kessler CM; Catchatourian R; Rondelli D; Silver RT; Bacigalupo A; Nagler A; Kremyanskaya M; Levine MF; Arango Ossa JE; McGovern E; Sandy L; Salama ME; Najfeld V; Tripodi J; Farnoud N; Penson AV; Weinberg RS; Price L; Goldberg JD; Barbui T; Marchioli R; Tognoni G; Rampal RK; Mesa RA; Dueck AC; Hoffman R
Blood; 2022 May; 139(19):2931-2941. PubMed ID: 35007321
[TBL] [Abstract][Full Text] [Related]
17. Polycythemia is associated with bone loss and reduced osteoblast activity in mice.
Oikonomidou PR; Casu C; Yang Z; Crielaard B; Shim JH; Rivella S; Vogiatzi MG
Osteoporos Int; 2016 Apr; 27(4):1559-1568. PubMed ID: 26650379
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic options for patients with polycythemia vera and essential thrombocythemia refractory/resistant to hydroxyurea.
Sever M; Newberry KJ; Verstovsek S
Leuk Lymphoma; 2014 Dec; 55(12):2685-90. PubMed ID: 24524340
[TBL] [Abstract][Full Text] [Related]
19. JAK2 ex13InDel drives oncogenic transformation and is associated with chronic eosinophilic leukemia and polycythemia vera.
Patel AB; Franzini A; Leroy E; Kim SJ; Pomicter AD; Genet L; Xiao M; Yan D; Ahmann JM; Agarwal AM; Clair P; Addada J; Lambert J; Salmon M; Gleich GJ; Cross NCP; Constantinescu SN; O'Hare T; Prchal JT; Deininger MW
Blood; 2019 Dec; 134(26):2388-2398. PubMed ID: 31697804
[TBL] [Abstract][Full Text] [Related]
20. [How I manage polycythemia].
Lombardo G; Hafraoui K; Beguin Y; Vertenoeil G
Rev Med Liege; 2024 Feb; 79(2):110-115. PubMed ID: 38356428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
